Pediatric Cancer: A Comprehensive Review. Part II: Chemotherapy,Monoclonal Antibodies and Tyrosine Kinase Inhibitors

DeVita VT Hellman S Rosenberg SA . Cancer: principles and practice of oncology. 8th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2008.

Dipiro JT Talbert RL Yee GC Pharmacotherapy: a pathophysiologic approach. 7th ed. New York: McGraw-Hill Companies; 2008.

Perry MC . The chemotherapy source book. 4th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2008.

Leigh R Furczon E . Biologics: an overview. Can Pharm J 2010;143(Suppl 1):S1–3.

Atalay C . Multi-drug resistance in cancer. Expert Opin Ther Pat 2007;17(5):511–20.

Agarwal B . Biological therapy for pediatric malignancy: current perspectives. Indian J Pediatr 2008;75:839–44.

Ma WW Adjei AA . Novel agents on the horizon for cancer therapy. CA Cancer J Clin 2009;59:111–37.

Heimann DM Weiner LM . Monoclonal antibodies in therapy of solid tumors. Surg Oncol Clin N Am 2007;16:775–92.

Cheson BD Leonard JP . Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 2008;359(6):613–26.

Sharkley RM Goldenberg DM . Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Adv Drug Deliv Rev 2008;60:1407–20.

Finn OJ . Molecular origins of cancer: cancer immunology. N Engl J Med 2008;358(25):2704–15.

Attias D Weitzman S . The efficacy of rituximab in high-grade pediatric B-cell lymphoma/leukemia: a review of available evidence. Curr Opin Pediatr 2008;20:17–22.

Shah M Agarwal B . Recent advances in management of acute myeloid leukemia (AML). Indian J Pediatr 2008;75:831–7.

Yu AL Gilman AL Ozkaynak MF A phase III randomized trial of the chimeric anti-GD2 antibody ch14.18 with GM-CSF and IL2 as immunotherapy following dose intensive chemotherapy for high-risk neuroblastoma: Children's Oncology Group (COG) study ANBL0032. J Clin Oncol 2009;27:15s.

Tonini GP Pistoia V . Molecularly guided therapy of neuro-blastoma: a review of different approaches. Curr Pharm Des 2006;12(18):2303–17.

Rossler J Geoerger B Taylor M Small molecule tyro-sine kinase inhibitors: potential role in pediatric malignant solid tumors. Curr Cancer Drug Targets 2008;8:76–85.

Skolnik JM Adamson PC . Tyrosine kinase inhibitors in pediatric malignancies. Cancer Invest 2007;25(7):606–12.

Crawford J MacDonald T Packer R . Medulloblastoma in childhood: new biological advances. Lancet Neurol 2007;6(12):1073–5.

Ludwig JA . Ewing sarcoma: historical perspective, current state of the art, and opportunities for targeted therapy in the future. Curr Opin Oncol 2008;20(4):412–8.

Uren A Toretsky JA . Pediatric malignancies provide unique cancer therapy targets. Curr Opin Pediatr 2005;17:14–9.

Kang SP Saif MW . Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer — identification, prevention, and management. J Support Oncol 2007;5(9):451–7.

Lacouture ME Melosky BL . Cutaneous reactions to anti-cancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective. Skin Therapy Lett 2007;12(6):1–5.

Gerber DE . Targeted therapies: a new generation of cancer treatment. Am Fam Physician 2008;77(3):311–9.

Novartis Oncology. DOVITINIB (TKI258) and BGJ398. Available: www.novartisoncology.com/research-innovation/pipeline/tki258.jsp (accessed May 29, 2010).